Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial

NCT05599516 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

16000

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
Coronavirus Infections

Interventions

BIOLOGICAL: LIBP-Rec-Vaccine
BIOLOGICAL: BIBP-Rec-Vaccine
BIOLOGICAL: placebo

Sponsor

National Vaccine and Serum Institute, China

Collaborators

[object Object]
[object Object]
[object Object]